#LivingInnovation

Welcome to Pfizer EU Policy

We partner with EU policy-makers and other stakeholders, driven by our purpose: Breakthroughs that change patients’ lives.

Learn more about our team and vision to contribute to more pro-patient and pro-innovation policies in the EU. And don’t hesitate to follow @PfizerEUPolicy on Twitter!

Learn More

scroll-down

Tobias Schulz: Health Data

Pfizer Germany Senior Manager, Policy and Public Affairs, built a career on making sure that health data is used in the best ways it can be for patients and society

Learn more

Bharati Shivalkar: Women at Heart

Pfizer’s BeLux Country Medical Director is passionate about fighting cardiovascular disease and empowering women

Learn more

Isabella Grueso: Beating Cancer

Pfizer’s Global Breast Cancer & Precision Medicine Policy Director grew up seeing the importance of Access to Medicines, and applies these lessons to breast cancer policy today

Learn more

Jo Atkinson: Fighting Resistant Infections

Pfizer’s Anti-Infectives Product Lead highlights the importance of R&D with a focus on AMR patients.

Learn more

Research and Development in the Pharmaceutical Industry

A Complex System Delivering Breakthroughs that Change Patients’ Lives
Research and development (R&D) is the foundation for discovering innovative medicines and vaccines that change patients’ lives. Pfizer’s R&D program is designed to develop safe and effective breakthroughs for patients across the globe.

Learn more

Video

2:20 min

The EU Pharma Strategy: Pfizer's Vision

We are witnessing a once-in-a-generation legislative revision in Europe.

As a partner of the EU institutions, we aim to ensure that the Pharmaceutical Strategy for Europe delivers both for patients and for innovation. We believe these goals can and should be pursued in parallel.

Meet the Team

EU Register of Interest Representatives # 4263301811-33

@PfizerEUPolicy Mar 22

#COVID19 has put a strain on billions of people worldwide. The economic consequences of the pandemic have been recently explored in a white paper by @TheEconomist, accessible here: https://t.co/TbLdZ2gcez #LivingInnovation

@PfizerEUPolicy Mar 21

Medical #innovation is worldwide. 🌍 That's why, as a leading regulator, the EU medicines regulatory network needs to continue to support efforts to harmonise regulatory requirements globally through the @ICH_news, the PIC/S, and other relevant organisations. #LivingInnovation https://t.co/Uw6772K6vG

@PfizerEUPolicy Mar 20

The Orphan and Paediatric Regulations have been major successes for 🇪🇺 patients. We need to maintain support for R&D for these very small patient populations - which is why updated rules must be carefully considered. Read how here 👉 https://t.co/AEXW0ymRWj #LivingInnovation https://t.co/nncJKssV2m

@PfizerEUPolicy Mar 17

Regulatory evolution is essential to meet new health challenges. The EU could collaborate with regulatory bodies around the world and work in synergy with Asian and American institutions. #LivingInnovation Learn more at: https://t.co/lmbktqdy8L https://t.co/ogcxQZlMmD

@PfizerEUPolicy Mar 16

What does a supportive and responsive regulatory framework in Europe look like? ✅ Prevention and early care ✅ Planning ahead ✅ Reaping the benefits of #digitalisation ✅ Focusing on people and outcomes It is all part of #LivingInnovation 👇

@PfizerEUPolicy Mar 15

The EU and its Member States have recognised the need for reform to attract #investment into R&D targeting #AMR. One thing that can be done? ✔️ Align AMR research funding, at national and EU level, with the scale of the threat #LivingInnovation

@PfizerEUPolicy Mar 14

Our personal experience often defines what matters the most in our lives. Jo Atkinson, Pfizer Anti-infectives Product Lead, found a calling in fighting #AMR while growing up in her father's practice in South Africa. #LivingInnovation See her story 👇

@PfizerEUPolicy Mar 13

Everyone needs to be aware of the growing issue of #AMR. By 2050 it could take 10 million lives per year globally, more than cancer. To address the threat, we need: ✔️ Push mechanisms ✔️ Novel pull mechanisms ✔️ Reimbursement and HTA reform #LivingInnovation

@PfizerEUPolicy Mar 10

Did you know that the life sciences sector supports 3-4x as many jobs indirectly as it does directly? It highlights the importance of R&D spending. #LivingInnovation

@PfizerEUPolicy Mar 9

Our CEO @AlbertBourla provides a comprehensive look at how public-private partnerships can help address global health equity in his latest LinkedIn article. Read more: https://t.co/n30HX9Ugzu #LivingInnovation